Literature DB >> 7625795

Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates.

E J Goldstein1, C A Nesbit, D M Citron.   

Abstract

The activities of sparfloxacin, levofloxacin, Bay y 3118, azithromycin, cefprozil, loracarbef, and nine other oral antimicrobial agents against 194 aerobic and anaerobic clinical bite wound isolates were determined by the agar dilution method. Sparfloxacin, levofloxacin, and Bay y 3118 were active against all aerobic isolates (MICs at which 90% of the isolates are inhibited [MIC90], < or = 1.0 microgram/ml for sparfloxacin and levofloxacin and 0.1 microgram/ml for Bay y 3118) and many anaerobic isolates, with the exception of the fusobacteria. Azithromycin was more active than erythromycin by 1 to 2 dilutions against many aerobes, including Pasteurella multocida and Eikenella corrodens, and by 2 to 4 dilutions against anaerobic isolates. Cefprozil was more active (MIC90, < or = 1 microgram/ml) than loracarbef (MIC90, < or = 4 micrograms/ml) against aerobic gram-positive isolates, but both had poor activity (MIC90, > or = 16 micrograms/ml) against peptostreptococci. Both cefprozil and loracarbef had MIC90s of < or = 0.5 micrograms/ml against P. multocida.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7625795      PMCID: PMC162690          DOI: 10.1128/AAC.39.5.1097

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  In vitro activity of sparfloxacin.

Authors:  N X Chin; J W Gu; K W Yu; Y X Zhang; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-08       Impact factor: 3.267

3.  Prophylactic antibiotics in common dog bite wounds: a controlled study.

Authors:  M Callaham
Journal:  Ann Emerg Med       Date:  1980-08       Impact factor: 5.721

Review 4.  Bite wounds and infection.

Authors:  E J Goldstein
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

5.  In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria.

Authors:  M D Kitzis; F W Goldstein; M Miégi; J F Acar
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  Bacteriology of human and animal bite wounds.

Authors:  E J Goldstein; D M Citron; B Wield; U Blachman; V L Sutter; T A Miller; S M Finegold
Journal:  J Clin Microbiol       Date:  1978-12       Impact factor: 5.948

7.  Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

8.  Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

9.  The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.

Authors:  R Wise; J M Andrews; N Brenwald
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

10.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

View more
  11 in total

1.  Postoperative care of the facial laceration.

Authors:  Nicholas Medel; Neeraj Panchal; Edward Ellis
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2010-12

2.  Pasteurella multocida infection of a total knee arthroplasty after a "dog lick".

Authors:  B Heym; F Jouve; M Lemoal; A Veil-Picard; A Lortat-Jacob; M H Nicolas-Chanoine
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2006-02-09       Impact factor: 4.342

3.  When your best friend bites: A note on dog and cat bites.

Authors:  H D Davies
Journal:  Can J Infect Dis       Date:  2000-09

4.  Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.

Authors:  E J Goldstein; D M Citron; C V Merriam; Y Warren; K Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.

Authors:  H M Wexler; E Molitoris; D Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  When your best friend bites: A note on dog and cat bites.

Authors:  H D Davies
Journal:  Paediatr Child Health       Date:  2000-10       Impact factor: 2.253

Review 7.  Azithromycin. A review of its use in paediatric infectious diseases.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

Review 8.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

9.  Susceptibilities of bovine summer mastitis bacteria to antimicrobial agents.

Authors:  H Jousimies-Somer; S Pyörälä; A Kanervo
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 10.  International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

Authors:  Thomas M File; James S Tan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.